Skip to main content
. 2020 Jun 24;95(9):1038–1046. doi: 10.1002/ajh.25875

FIGURE 2.

FIGURE 2

Disease severity categories at baseline and after 2 years of eliglustat therapy in treatment‐naïve patients. EM, extensive metabolizer; F, female; IM, intermediate metabolizer; M, male; MN, multiples of normal organ size; PM, poor metabolizer; URM, ultra‐rapid metabolizer